Public Health Emergency Preparedness
This resource was part of AHRQ's Public Health Emergency Preparedness program, which was discontinued on June 30, 2011, in a realignment of Federal efforts.
This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Appendix 4 (continued)
4.2 Drug Identification (DI) Application
The DI application will allow inbound callers to obtain self-service identification
for the different appearances of antibiotic drugs that are being dispensed at POD
sites during a public health emergency. The callers should be given clear directions
from the menu messages and be able to repeat messages or descriptions of the
identified drug. The caller should also have the ability to identify more than
one drug appearance per call or to repeat messages. The application should have messages
that refer callers to other resources if they cannot utilize the self-service
application or the rug appearance is not included as an option (if it could be
modified to automatically transfer them to an information provider for assistance).
This application will be designed to accommodate one language selection (English).
However, future programming changes may be need for additional language selections
that the caller will select at the beginning of the call (just as with the other
three applications). The DI application will also provide reporting on how many
callers selected each of the drug identification options. The DI application
should be able to accommodate options for all expected antibiotic drug appearances
that are to be distributed.
DI Main Call Flow (English)
DOXY Cap Flow
DOXY Tab Flow
General & Ciproflaxacin Announcements
Levaquin & Doxycycline Announcements
Return to Appendix 4 Contents
Return to Report Contents
Proceed to Next Section